## Index

- **N-acetylcysteine (NAC)** 181
- **activator protein-1 (AP-1)** 39
- **adenylate cyclase (ADCY)** 61
- **adhesion molecules** 172–3
- **airflow obstruction site** 4
- **airway (bronchial) hyperresponsiveness (AHR)** 6, 10, 212, 213
  - *Chlamydomphila (Chlamydia) pneumoniae* 240
  - *Mycoplasma pneumoniae* 240–1
- **airway innervation** 268–9
  - parasympathetic system 269–70
- **airway remodelling** 285
- **allergic rhinitis**
  - immunoglobulin E (IgE) 218–20
- **alpha-1-antiprotease deficiency** 6
- **anti-infective treatments in asthma and COPD** 232–4, 259–60
- **acute exacerbations of asthma** 236
  - current guidelines 234
    - British Thoracic Society (BTS) 234–5
    - Canadian 235
    - European Respiratory Society/American Thoracic Society 235
    - National Asthma Education and Prevention Program Expert Panel (NAEPP) 234
    - National Institute for Health and Clinical Excellence (NICE) 235
  - increased susceptibility to infections in asthma 236–7
  - role of atypical infections in asthma 237
  - role of atypical infections in asthma exacerbations
    - *Chlamydomphila (Chlamydia) pneumoniae* 239
    - *Mycoplasma pneumoniae* 239–40
  - role of macrolide and ketolide antibiotics 241–4
  - role of viruses in asthma exacerbations 244
    - antiviral therapy 245–50
    - rhinoviruses 244–5
  - role of atypical infections in asthma exacerbations
    - *Chlamydomphila (Chlamydia) pneumoniae* 239
    - *Mycoplasma pneumoniae* 239–40
- **antioxidants** 181–2
- **chemokines** 166–9
- **cytokines** 169–72
- **growth factor blockers** 173
- **immunomodulation** 182–5
- **infections** 174–5
- **intracellular signalling pathways** 175–81
- **macrolide and ketolide antibiotics** 241–4
- **mucus production** 173–4
- **need for new treatments** 160–2
- **transcription factor inhibition** 178–81
- **antioxidants** 181–2
- **apremilast** 299
- **arformoterol** 56
- **arterial carbon dioxide tension (P_aCO_2)** 4–5
- **arteriosclerosis** 7
- **aspirin-exacerbated respiratory disease (EARD)** 7
- **aspirin-sensitive asthma (AIA)** 7
- **asthma**
  - acute exacerbations 236
  - adhesion molecules 172–3
  - airflow hyperresponsiveness (AHR) 10
  - β-blockers 10–11
  - role of atypical infections in asthma 237
  - role of atypical infections in asthma exacerbations
    - *Chlamydomphila (Chlamydia) pneumoniae* 239
    - *Mycoplasma pneumoniae* 239–40
  - role of macrolide and ketolide antibiotics 241–4
  - role of viruses in asthma exacerbations 244
    - antiviral therapy 245–50
    - rhinoviruses 244–5
- **anti-inflammatory treatments, novel** 154, 185–6
  - antioxidants 181–2
  - adhesion molecules 172–3
  - chemokines 166–9
  - cytokines 169–72
  - growth factor blockers 173
  - immunomodulation 182–5
  - improving current therapies 162–5
  - infections 174–5
  - intracellular signalling pathways 175–81
  - mucus production 173–4
  - need for new treatments 160–2
  - transcription factor inhibition 178–81
  - antioxidants 181–2

---

asthma (Continued)
atypical bacteria
proposed pathological mechanisms 240
atypical bacteria in asthma exacerbations
*Chlamydophila (Chlamydia) pneumoniae* 239
*Mycoplasma pneumoniae* 239–40
atypical bacteria in stable asthma
*Chlamydophila (Chlamydia) pneumoniae* 238
*Mycoplasma pneumoniae* 238
cellular inflammation 8
distribution and consequences 9–10
epithelial injury 9, 10
chemokines 166–9
cholingeric mechanisms 270–1
clinical features 3
combination therapy
LABAs and inhaled corticosteroids (ICS) 137–9
comorbidities 7
corticosteroid-resistant (CSR) 161
current anti-infection guidelines
British Thoracic Society (BTS) 234–5
National Asthma Education and Prevention Program Expert Panel (NAEPP) 234
current therapies 158–9
differential diagnosis 5, 11–12
glucocorticoids, inhaled
dose–response characteristics 44
efficacy 43–4
growth factor blockers 173
immunoglobulin E (IgE) 215–18
immunomodulation and anti-allergy treatments 182–5
increased susceptibility to infections 236–7
infections 174–5
kinase inhibitors 175–8
LAAC bronchodilators 283
acute exacerbations/viral infections 286
airway remodelling 285
asthma and GERD 285
everly sufferers 283–4
exercise-induced asthma (EIA) 286
nocturnal asthma 285
safety considerations 286–7
severe asthma 284–5
LABAs 82–4
mucus cells 174–5
nature 154–7
new therapies, need for 160–1
compounds under development 164
pathophysiology 1–3, 12–13
pulmonary function abnormalities 3–5
pharmacological management 135–6
phosphodiesterase-4 inhibitors 175
predisposing factors 3
atopy 7
environmental 6
genetic 5–6
role of atypical infections 237
steroid-resistant 29–31, 31–2
smoking 30–1
steroid treatment 136–7
targets of therapy 204
T-cell derived and proinflammatory cytokines 169
IL-4 and IL-13 169–70
IL-5 170–1
IL-10 and IL-12 171
thymic stromal lymphopoietin (TSLP) 171
tumor necrosis factor-α (TNF-α) 171–2
transcription factor inhibitors 178–81
ultra-LABAs
carmoterol 90
indacaterol 87–8
vilanterol trifenatate 91–2
vaccination 257–8
viruses
antiviral therapy 245–50
role in asthma exacerbations 244–5
atopy 6
risk factor for asthma 7
AU-rich elements (AREs) 26–7
azithromycin 241–4
basophils 8
beclomethasone dipropionate (BDP) 17, 41, 136
inhaled 42
beta-receptor blockers (β-blockers) 10–11
asthma 67–8
biological therapies for COPD 311–12, 323
development 320–3
bronchial thermoplasty 222–3
bronchodilators
response 4
bronchial hyperresponsiveness (BHR) see airway hyperresponsiveness (AHR)
bruising of skin  
side effects of glucocorticoids 49  
budesonide 17, 41, 139  
inhaled 42–3  
butylated hydroxyanisole 181  
calcitonin gene-related peptide 162  
carbon dioxide, arterial tension 4–5  
carmoterol 54, 89–90  
asthma 90  
COPD 90–1  
preclinical development 90  
cataracts, posterior subcapsular  
side effects of glucocorticoids 48  
cellular inflammation  
asthma 8  
COPD 8–9  
distribution and consequences 9–10  
cethromycin 241–4  
chemokine antagonists 224  
chemokines 166–9  
COPD 315, 319–20  
*Chlamydophila* (*Chlamydia*) pneumoniae 174, 232, 237  
proposed pathological mechanisms 240  
role in asthma exacerbations 239  
role in stable asthma 238  
cholinergic mechanisms in asthma and COPD 270–1  
chromatin 18  
chronic obstructive lung disease (GOLD) 45  
chronic obstructive pulmonary disease (COPD) 340–1  
adhesion molecules 172–3  
airway hyperresponsiveness (AHR) 10  
antioxidants 181–2  
beta-agonist therapy and adverse events 115–16  
biological therapies 311–12, 323  
development 320–3  
cellular inflammation 8–9  
distribution and consequences 9–10  
epithelial injury 9, 10  
chemokines 166–9, 315, 319–20  
cholinergic mechanisms 270–1  
clinical features 3  
comorbidities 7  
current anti-infection guidelines  
Canadian 235  
European Respiratory Society/American Thoracic Society 235  
National Institute for Health and Clinical Excellence (NICE) 235  
current therapies 159–60  
anticholinergics 160  
cytokines 315–19  
differential diagnosis 5, 11–12  
exacerbations  
antibiotic use 253–5  
antiviral use 255–6  
causes 251–3  
role of anti-infective therapy 250–1  
glucocorticoids, inhaled 45–6  
growth factor blockers 173  
immunomodulation and anti-allergy treatments 182–5  
infections 174–5  
kine inhibitors 175–8  
LAAC bronchodilators 271–2  
airway function 272–5  
alleviation of chronic activity-related dyspnoea 276–7  
disease progression 280–1  
effect on acute exacerbations 278–80  
improvement of exercise endurance 277–8  
lung volume deflation 275–6  
mortality 281–2  
safety considerations 282  
LABAs 84–6, 140  
mucus cells 174–5  
nature 154–7  
new therapies, need for 161–2  
compounds under development 164  
pathophysiology 1–3, 12–13, 312–15  
pulmonary function abnormalities 3–5  
pharmacological management 135–6  
phosphodiesterase (PDE) inhibitors 296–7, 298, 302–4, 306  
future prospects 305–6  
management plans 305  
side effects 304–5  
systemic processes 304  
phosphodiesterase-4 inhibitors 175  
predisposing factors 3  
environmental 6  
genetic 5–6  
role of LABA therapy 117–20
chronic obstructive pulmonary disease (COPD) (Continued)
safety and efficacy of LABAs 116–17
conclusions 120
stable
antibiotic use 256–7
steroid treatment 140
steroid-resistant 31–2
T-cell derived and proinflammatory cytokines 169
IL-4 and IL-13 169–70
IL-5 170–1
IL-10 and IL-12 171
thymic stromal lymphopoietin (TSLP) 171
tumor necrosis factor-α (TNF-α) 171–2
transcription factor inhibitors 178–81
treatment strategies 334
trial results 337–40
ultra-LABAs
carmoterol 90–1
indacaterol 88–9
vilanterol trifenatate 92
vaccinations 258–9
combination therapy
LABAs and inhaled corticosteroids (ICS) 137–9
combination inhalers versus separate inhalers 141–3
novel biological agents 203, 224–5
DNA vaccines 220–2
future directions 222–4
immunoglobulin E (IgE) 215–20
interleukin-4 (IL-4) 204–7
interleukin-5 (IL-5) 207–11
interleukin-13 (IL-13) 211–12
targets of therapy 204
tumor necrosis factor-α (TNF-α) 212–15
corticosteroids see glucocorticoids
corticosteroid-resistant (CSR) asthma 161
cyclical adenosine monophosphate response element binding protein (CREB)-binding protein (CBP) 18
cytokines 8, 20, 169
COPD 315–19
interleukin-4 (IL-4) 169–70
interleukin-5 (IL-5) 170–1
interleukin-6 (IL-6) 316–17
interleukin-10 (IL-10) 171, 317
interleukin-12 (IL-12) 171
interleukin-13 (IL-13) 169–70
interleukin-17 (IL-17) 318–19
interleukin-18 (IL-18) 318–19
interleukin-23 (IL-23) 318–19
thymic stromal lymphopoietin (TSLP) 171
tumor necrosis factor-α (TNF-α) 171–2, 316
dendritic cells (DCs) 8, 20, 182–3, 315
depression 7
dermatitis 7
diagnosis
differential between asthma and COPD 5
differential for other conditions 11–12
diffusion capacity 5
DNA vaccines 220–2
estase 9
emphysema 9
endothelial cells 20
environmental risk factors for asthma and COPD 6
eosinophils 20, 315
asthma 8
COPD 9
eotaxin 8
epithelial cells 20, 315
epithelial growth factor receptor (EGFR) 173, 223
epithelial injury in asthma and COPD 9, 10
erythromycin 241–4
fenoterol 81
safety 103–5
fibroblasts 315
flunisolide 17
inhaled 42
fluticasone 85
fluticasone furoate 137
fluticasone propionate (FP) 17, 41, 139
inhaled 42, 43
formoterol 53, 54, 81, 139
asthma 64
eficacy combined with ICSs 110
COPD 84
isomers 55
membrane diffusion 62
safety 102–3
gastro-oesophageal reflux disease (GERD) 285
gemifloxacin 254
genetic risk factors for asthma and COPD 5–6
glucocorticoid receptors (GRs) 20–1, 38, 40
acetylation 26
steroid-resistant asthma 29–30
glucocorticoid response elements (GREs) 21, 39, 40
glucocorticoids 16, 33, 38, 49
absorption and fate 41
administration 39–41
anti-inflammatory activity 38–9
$\beta_2$-adrenergic receptor interactions 32–3
cellular effects 19–20
efficacy in asthma 43–4
dose–response characteristics 44
efficacy in COPD 45–6
gene transcription activation 22–3
anti-inflammatory genes 23
side effect genes 23
inflammatory gene suppression 23–4
glucocorticoid receptor acetylation 26
histone acetylation 25–6
interaction with transcription factors 24–5
non-transcriptional effects 26–7
other histone modifications 26
signal transduction pathways 27–9
inhaled preparations 41
beclomethasone dipropionate (BDP) 42
budesonide 42–3
ciclesonide 43
flunisolide 42
fluticasone propionate (FP) 43
mometasone 43
triamcinolone 42
reduced systemic side effects 162–4
resistance 29
asthma 29–31
COPD 31–2
side effects 46
bruising of skin 49
growth retardation in children 48
local 46
lung infection risk 49
osteoporosis 48
posterior subcapsular cataracts 48
systemic 46
upon HPA axis 46–8
structures 16–17
G-protein-coupled receptor (GPCR) 56
granulocyte-macrophage colony-stimulating factor (GM-CSF) 204, 317–18
growth factor blockers 173
growth retardation in children
side effects of glucocorticoids 48
Haemophilus influenzae 233
heart disease 7
histamine 8
histone acetyltransferases (HAT) 18–19, 39, 40
histone deacetylases (HDACs) 19, 25–6, 39, 40
hydrocortisone 17
hypothalamic–pituitary–adrenal (HPA) axis
side effects of glucocorticoids 46–8
immunoglobulin E (IgE)
allergic rhinitis 218–20
asthma 215–18
immunomodulation 182–5
immunostimulatory oligodeoxynucleotides 185
indacaterol 54, 86
asthma 87–8
COPD 88–9
membrane diffusion 62
preclinical development 86–7
infections in asthma and COPD 174–5
inflammation
gene suppression by glucocorticoids 23–4
glucocorticoid receptor acetylation 26
histone acetylation 25–6
interaction with transcription factors 24–5
non-transcriptional effects 26–7
other histone modifications 26
signal transduction pathways 27–9
molecular basis 17–18
chromatin remodelling 18
histone acetyltransferases (HAT) 18–19
histone deacetylases (HDACs) 19, 25–6
inhaled corticosteroids see under glucocorticoids
inositol phosphate (IP) 68–9
interferons 184–5
antiviral therapy 246–8
interleukins 8
interleukin-4 (IL-4) 169–70, 204–7
interleukin-5 (IL-5) 170–1, 207–11
interleukin-6 (IL-6) 316–17
interleukin-10 (IL-10) 171, 317
interleukin-12 (IL-12) 171
interleukin-13 (IL-13) 169–70, 211–12
interleukin-17 (IL-17) 318–19
interleukin-18 (IL-18) 318–19
interleukin-23 (IL-23) 318–19
ipratropium 84
isoprenaline 81
ketolide antibiotics
role in asthma 241–4
kinase inhibitors 175–8, 223–4
late asthmatic response (LAR) 208
leukotrienes 8
levofloxacin 254
lipid mediator blockade 164–5
5-lipoxygenase-activating protein (FLAP) inhibitors 165
long-acting anticholinergic (LAAC)
bronchodilators 271
asthma 283
acute exacerbations/viral infections 286
airway remodelling 285
asthma and GERD 285
elderly sufferers 283–4
exercise-induced asthma (EIA) 286
nocturnal asthma 285
safety considerations 286–7
severe asthma 284–5
combined COPD/asthma 284
COPD 271–2
airway function 272–5
alleviation of chronic activity-related dyspnoea 276–7
disease progression 280–1
effect on acute exacerbations 278–80
improvement of exercise endurance 277–8
lung volume deflation 275–6
mortality 281–2
safety considerations 282
tiotropium bromide 271
long-acting antimuscarinic antagonists 268, 287–8
long-acting β2-adrenoceptor agonists (LABAs) 53–5, 73, 82
asthma 82–4
biochemical basis 68–9
COPD 84–6
dimers and oligomers 60
efficacy 64–7
efficacy combined with ICSs 110–13
safety conclusions 114–15
evidence for beneficial and adverse effects 113–14
functioning structure and signalling mode 58–60
future directions 127–8
Galenical forms 55–6
interactions with steroids 69–73
membrane diffusion model 61–3
non-receptor-mediated effects 68
pharmacogenomics 61, 120–6
regulation and desensitization 63–4
role in COPD 117–20, 140
safety 102–3
asthma-related mortality 103–5
asthma-related mortality increase 105–7
combination therapies 126–7
COPD 116–17
COPD conclusions 120
retrospective analyses 107–9
selectivity 56–8
lung infection risk	side effects of glucocorticoids 49
lymph nodes 8
macrolide antibiotics
role in asthma 241–4
macrophages 8, 20, 312–14
mast cells 8, 20
methylprednisolone 41
milveterol 91
mitogen-activated protein (MAP) 27–8
mitogen-activated protein kinase (MAPK) 28
steroid-resistant asthma 29
mometasone
inhaled 42, 43, 137
Moraxella catarrhalis 233
moxifloxacin 254
mucus cells 174–5
muscarinic receptors 269–70
Mycoplasma pneumoniae 174, 232, 237
proposed pathological mechanisms 240–1
role in asthma exacerbations 239–40
role in stable asthma 238
myofibroblasts 9
nacystelyn (NAL) 181
nadolol 67
nasal polyposis 7
natural killer (NK) cells 315
neutrophils 8, 9, 314
nitric oxide (NO) 181
non-steroidal anti-inflammatory drugs (NSAIDs)
in tolerance 7
nuclear factor of activated T-cells (NF-AT) 39, 179–80
nuclear factor-κB (NF-κB) 178
oglemilast 299
oligodeoxyribonucleotides (ODNs) 221
omalizumab
allergic rhinitis 218–20
asthma 215–18
osteoporosis 7
side effects of glucocorticoids 48
overlap between asthma and COPD 5
overlap syndrome 12
pathophysiology of asthma and COPD 1–3,
12–13, 312–15
clinical features compared 3
predisposing factors 3
pulmonary function abnormalities 3–4
airflow obstruction site 4
arterial carbon dioxide tension 4–5
bronchodilator response 4
comparison 4, 5
diffusion capacity 5
overlap between asthma and COPD 5, 12
peroxisome proliferator-activated receptors (PPARs) 180–1
phosphodiesterase inhibitors in COPD 296–7,
298, 302–4, 306
future prospects 305–6
management plans 305
side effects 304–5
systemic processes 304
phosphodiesterase-4 inhibitors 175
phosphodiesterases (PDEs) 297–298
pharmacological blocking agents of PDE4
298–9
biological effects 300–2
clinical effects 302–4
plasma cells 315
platelet-derived growth factor receptor
(PDGF-R) 223
pleconaril 245–6
prednisone 41
RANTES 8
resveratrol 181
revamilast 299
rhinitis 7
rhinitis, allergic see allergic rhinitis
rhinoviruses 244–5
rimiterol 81
risk factors for asthma and COPD
environmental 6
genetic 5–6
rolflumilast 175, 298, 301, 302–4
rolipram 298
ronomilast 298
roxithromycin 241–4
rufinamide 246

salbutamol 81
salegenin 93–4
salmeterol 53, 54, 81, 139
asthma 64
efficacy combined with ICSs 111–13
COPD 84
membrane diffusion 62
safety 102–3
increased asthma-related mortality 105–7
sarcoidosis 41
secretory leukoprotease inhibitor (SLPI) 22
short-acting \( \beta_2 \)-adrenoceptor agonists (SABAs) 53
asthma-related mortality 103–5
signal transducer and activator of transcription (STAT) 39, 180
sinus disease 7
sinus polyposis 7
skin bruising
side effects of glucocorticoids 49
smoking see cigarette smoking
squamous cell metaplasia 9
stem cell factor (SCF) 223
steroid resistance 29
asthma 29–31
smoking 30–1
COPD 31–2
steroids
asthma treatment 136–7
COPD treatment 140
interactions with LABAs 69–73
Streptococcus pneumoniae 233
Syk kinase inhibition 223–4

T-cells 314
T-lymphocytes 20
TATA box binding protein (TBP) 18
telithromycin 241–4
terbutaline 81

thymic stromal lymphopoietin (TSLP) 171
tiotropium bromide 84, 271, 333
tofinilast 299
Toll-like receptors (TLRs) 174
transcription factor inhibitors 178–81
transforming growth factor-\( \beta_1 \) (TGF-\( \beta_1 \)) 173
tremacamra 246
triamicinolone acetonide 17
inhaled 42
triple therapies for COPD 333, 340–1
ICS, LAMAs and LABAs combined 335–7
inhaled corticosteroids (ICS) 334–5
LAMAs and LABAs 333–4
treatment strategies 334
trial results 337–40
tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)) 171–2,
212–15, 316

ultra-long-acting \( \beta_2 \)-adrenoceptor agonists
(ultra-LABAs) 86, 95
BI-1744-CL (under development) 92–3
carmoterol 89–1
indacaterol 86–9
LAS-100977 (under development) 95
milveterol 91
salegenin 93–4
vilanterol trifenatate 91–2

vaccination 257
asthma 257–8
COPD 258–9
vasoactive intestinal peptide (VIP) 162
vilanterol trifenatate 91

viruses
role in asthma exacerbations 244
antiviral therapy 245–50
rhinoviruses 244–5

zanamivir 245
zileuton 164–5